Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
4.290
+0.190 (4.63%)
Dec 20, 2024, 4:00 PM EST - Market closed
Xenetic Biosciences Employees
Xenetic Biosciences had 4 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$630,857
Profits / Employee
-$1,019,315
Market Cap
6.62M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Star Equity Holdings | 171 |
| Syra Health | 162 |
| PAVmed | 107 |
| Kindly MD | 65 |
| Vincerx Pharma | 42 |
| Plus Therapeutics | 20 |
| ABVC BioPharma | 19 |
| Adial Pharmaceuticals | 7 |
XBIO News
- 4 days ago - Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - Accesswire
- 5 days ago - Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - Accesswire
- 16 days ago - Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program - Accesswire
- 4 weeks ago - Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis - Accesswire
- 5 weeks ago - Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - Accesswire
- 5 weeks ago - Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models - Accesswire
- 6 weeks ago - Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - Accesswire
- 2 months ago - Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 - Accesswire